Secukinumab in refractory non-infectious anterior uveitis
BackgroundSecukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Ophthalmology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fopht.2025.1491981/full |